US REGULATORY RECORDS
- FDA DMF records
- 1
- Active (A)
- 1
- Inactive (I)
- 0
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Review the Lenvatinib free-base filing before you request a specification. The supplied FDA snapshot has one Type II Drug Master File whose subject is exactly LENVATINIB. Salt, solvate and named crystal-form subjects stay outside this dataset.
CSV export requires an active subscription. The Lenvatinib filing in the table is already visible. Already subscribed? Sign in to export it.
This profile uses the Lenvatinib free-base identity, CAS 417716-92-8. A record is included only when the reported subject is exactly LENVATINIB after trimming. The workbook has no CAS field, so mesylate, besylate, solvate, route-code and named crystal-form subjects are excluded.
The supplied FDA snapshot contains 1 Type II record with the subject LENVATINIB. The free table shows that Lenvatinib filing. A subscription exports the same row as CSV and does not unlock another free-base row from this snapshot.
FDA list cutoff:
The count describes filings at the June 30, 2026 cutoff. Confirm the current activity status with FDA and the material specification with the holder before relying on the record.
$19.00 per month
$149.00 per year
Billed $149.00 every year
Lenvatinib coverage: 1 FDA DMF record. The free table already shows that filing, and the CSV sample contains the same row.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product.
US REGULATORY RECORDS
Read DMF 33195 for the reported holder, the initial submission date and the activity status. The holder name is the party listed on the filing. Confirm the manufacturing site separately during qualification. The same holder name also appears on a separate subject that names the mesylate; only this Lenvatinib subject is kept.
1Active (A)
0Inactive (I)
FDA uses A for active and I for inactive. This Lenvatinib entry is active in the snapshot. An active code does not establish permission to reference the file, an approved supplier or an available batch.
Free previewShowing 1 of 1 Lenvatinib records.
The FDA substance record identifies Lenvatinib free base by CAS 417716-92-8 and UNII EE083865G2 and lists E7080 as a synonym. PubChem CID 9823820 supplies the free-base formula and a computed molecular weight of 426.9 g/mol, and it lists deprecated CAS 942407-57-0 for the same free base. The LENVIMA label states that the capsule drug substance is the mesylate salt, with a salt molecular weight of 522.96. Capsule strengths of 4 mg and 10 mg are expressed as lenvatinib and equal 4.90 mg and 12.25 mg of the salt. PubChem CID 11237762 assigns that salt CAS 857890-39-2. The October 5, 2026 China CDE export has 23 related entries, all named 甲磺酸仑伐替尼, with 21 status A and 2 status I. The export does not use the free-base name or give a CAS number. Those registrations, and every FDA subject other than LENVATINIB, are outside this record set.
The formula and molecular weight below describe Lenvatinib free base. The label gives the mesylate salt a molecular weight of 522.96. When comparing specifications, check whether the assay is expressed as the free base or as the salt, and confirm the solid form against the intended material.
The CAS number is 417716-92-8. FDA identifies this Lenvatinib substance with UNII EE083865G2 and lists E7080 as a synonym. PubChem also lists deprecated CAS 942407-57-0 for the same free base. Use the CAS and the stated chemical form together when requesting a material specification.
The salt pairs the protonated base with methanesulfonate. The LENVIMA label identifies the capsule drug substance as that salt and expresses 4 mg and 10 mg strengths as the equivalent amount of lenvatinib, corresponding to 4.90 mg and 12.25 mg of the salt. PubChem assigns the salt CAS 857890-39-2. Mesylate, besylate, solvate and named crystal-form filings are outside this Lenvatinib record set.
The Q2 2026 workbook contains 1 Type II entry whose full subject is LENVATINIB after trimming. That filing is DMF 33195, reported holder MSN LABORATORIES PRIVATE LTD, first submitted on 2018-09-29, with status A. The same holder name appears on a separate subject that names the mesylate, and that filing is not in this set. Type II also covers intermediates and finished products, so the subject is checked separately. The file gives no CAS field for independent confirmation.
The October 5, 2026 CDE export contains 23 registrations named 甲磺酸仑伐替尼, with 21 status A and 2 status I. It does not use the free-base name and does not give a CAS number. Those rows describe mesylate registrations and are not mixed into this Lenvatinib dataset.
An A code indicates that DMF 33195 was active in the FDA snapshot. FDA reviews the technical contents in connection with an application that references the DMF. The activity code does not indicate FDA approval, and it does not confirm that the holder will authorize a reference or supply a batch.
Confirm DMF 33195, the free-base form and the assay basis, and the manufacturing site that would supply the intended batch. Request the applicable specification and the batch certificate of analysis. If an application will reference the file, ask the holder about a letter of authorization. Do not treat a mesylate, besylate, solvate or named crystal form as this record.
Official substance references, the supplied snapshots and FDA guidance for interpreting the records.
U.S. Food and Drug Administration
Identifies the free base by CAS 417716-92-8 and UNII EE083865G2, and lists E7080 among the synonyms.
“417716-92-8”
U.S. Food and Drug Administration
Synonyms and Mappings in FDA UNII record EE083865G2.
National Center for Biotechnology Information
Supplies the free-base formula and computed molecular weight, and lists deprecated CAS 942407-57-0 for the same substance.
“426.9 g/mol”
National Center for Biotechnology Information
Molecular Weight in the Computed Properties table for PubChem CID 9823820.
U.S. National Library of Medicine
States that the capsule drug substance is the mesylate salt, gives the salt molecular weight as 522.96, and expresses 4 mg and 10 mg strengths as quantities of the free base.
“equivalent to 4.90 mg or 12.25 mg of lenvatinib mesylate”
U.S. National Library of Medicine
Section 11, Description, of the LENVIMA labeling hosted by DailyMed.
National Center for Biotechnology Information
Identifies the mesylate salt by CAS 857890-39-2. That salt is outside this free-base record set.
“857890-39-2”
National Center for Biotechnology Information
Synonyms listed for PubChem CID 11237762.
U.S. Food and Drug Administration
The supplied workbook contains the selected filing at the June 30, 2026 cutoff. The official list page may show a newer quarter.
“LENVATINIB”
U.S. Food and Drug Administration
Reported SUBJECT of the selected Type II filing in worksheet 2Q2026-EXCEL.
U.S. Food and Drug Administration
Explains that a DMF can be referenced and that FDA reviews its technical contents with the application that cites it.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA explanation of Drug Master Files and review of applications that reference them.
U.S. Food and Drug Administration
Shows why a Type II classification alone does not establish that a filing covers the free base.
“Drug Substance, Drug Substance Intermediate”
U.S. Food and Drug Administration
FDA Type II Drug Master File category heading.
Center for Drug Evaluation, National Medical Products Administration
The supplied export names all 23 related registrations as the mesylate. Twenty-one are status A and two are status I.
“甲磺酸仑伐替尼”
Center for Drug Evaluation, National Medical Products Administration
Reported substance name in the supplied eleven-column CDE API registry export.
The free table already shows the one Lenvatinib filing whose subject is exactly LENVATINIB. Subscribe to export that FDA row as CSV and to search other API datasets on APIRFQ. The subscription does not add another free-base row from this snapshot.
CSV export requires an active subscription. The Lenvatinib filing in the table is already visible. Already subscribed? Sign in to export it.
Include the DMF number or the field in question and a link to the supporting source.
Email APIRFQ support